For research use only. Not for therapeutic Use.
CYP19A1/CYP11B2-IN-1 (Cat No.: M032813) is a dual inhibitor targeting both CYP19A1 (aromatase) and CYP11B2 (aldosterone synthase), enzymes involved in steroidogenesis. By inhibiting these enzymes, CYP19A1/CYP11B2-IN-1 reduces the production of estrogen and aldosterone, which are key hormones in various physiological processes. This dual inhibition is particularly promising for the treatment of hormone-dependent cancers, such as breast cancer, and conditions related to excessive aldosterone, like hypertension and heart failure. Its potential in endocrine therapy and disease modulation is under active investigation.
| CAS Number | 183500-36-9 |
| Synonyms | 4-[[5-(hydroxymethyl)imidazol-1-yl]methyl]benzonitrile |
| Molecular Formula | C12H11N3O |
| Purity | ≥95% |
| InChI | InChI=1S/C12H11N3O/c13-5-10-1-3-11(4-2-10)7-15-9-14-6-12(15)8-16/h1-4,6,9,16H,7-8H2 |
| InChIKey | ACFSBQWDVYWNRT-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC=C1CN2C=NC=C2CO)C#N |
| Reference | [1]. Tinivella A, et al. Discovery of a Potent Dual Inhibitor of Aromatase and Aldosterone Synthase. ACS Pharmacology & Translational Science. 2023 Nov 23. |
